Compare HTLD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | MNKD |
|---|---|---|
| Founded | 1978 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2004 |
| Metric | HTLD | MNKD |
|---|---|---|
| Price | $11.16 | $3.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $13.20 | $7.84 |
| AVG Volume (30 Days) | 670.2K | ★ 4.6M |
| Earning Date | 10-30-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $26.86 |
| Revenue Next Year | $8.43 | $13.64 |
| P/E Ratio | $162.14 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $7.00 | $2.23 |
| 52 Week High | $16.64 | $6.51 |
| Indicator | HTLD | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 37.41 |
| Support Level | $10.67 | $3.24 |
| Resistance Level | $11.48 | $4.23 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.83 | 11.85 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.